neobookRx
GuidelinesOther guideline

References - NICD Influenza

References - NICD Influenza Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et al. Mortality amongst Patients with Influenza-Associated Severe Acute Respiratory Illness, South Africa, 2009-2013. PloS one 2015; 10(3):e0118884. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systemati

References - NICD Influenza

  1. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et al. Mortality amongst Patients with Influenza-Associated Severe Acute Respiratory Illness, South Africa, 2009-2013. PloS one 2015; 10(3):e0118884.
  2. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011; 378(9807):1917-1930.
  3. World Health Organization. Seasonal influenza. In. WHO website 2016.
  4. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. The Lancet; 391(10127):1285-1300.
  5. Ruuskanen Olli O, E LE, LC JLC, DR MDR. 2011.
  6. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet InfectDis 2012; 12(9):687-695.
  7. Cohen C, Simonsen L, Kang JW, Miller M, McAnerney J, Blumberg L, et al. Elevated influenza- related excess mortality in South African elderly individuals, 1998-2005. ClinInfectDis 2010; 51(12):1362-1369.
  8. Tempia S, Walaza S, Moyes J, Cohen AL, McMorrow ML, Treurnicht FK, et al. Quantifying How Different Clinical Presentations, Levels of Severity, and Healthcare Attendance Shape the Burden of Influenza-associated Illness: A Modeling Study From South Africa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019; 69(6):1036-1048.
  9. Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, et al. Deaths Associated with Respiratory Syncytial and Influenza Viruses among Persons >/=5 Years of Age in HIV-Prevalent Area, South Africa, 1998-2009. Emerging infectious diseases 2015; 21(4):600-608.
  10. Tempia S, Walaza S, Cohen AL, von Mollendorf C, Moyes J, McAnerney JM, et al. Mortality Associated with Seasonal and Pandemic Influenza among Pregnant and Non-Pregnant Women of Childbearing Age in a High HIV Prevalence Setting – South Africa, 1999-2009. Clinical Infectious Diseases 2015.
  11. Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, et al. Mortality associated with seasonal and pandemic influenza and respiratory syncytial virus among children <5 years of age in a high HIV prevalence setting--South Africa, 1998-2009. ClinInfectDis 2014; 58(9):1241-1249.
  12. Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, et al. Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009-2011. EmergInfectDis 2013; 19(11):1766-1774.
  13. Murray J, Cohen A, Walaza S, Groome M, Madhi S, Variava E, et al. Determining the Provincial and National Burden of Influenza-Associated Severe Acute Respiratory Illness in South Africa Using a Rapid Assessment Methodology. PloS one 2015; 10(7):e0132078.
  14. Tempia S, Walaza S, Moyes J, Cohen AL, von Mollendorf C, Treurnicht FK, et al. Risk Factors for Influenza-Associated Severe Acute Respiratory Illness Hospitalization in South Africa, 2012–2015. Open forum infectious diseases 2017; 4(1):ofw262-ofw262.
  15. Walaza S, Cohen C, Nanoo A, Cohen AL, McAnerney J, von Mollendorf C, et al. Excess Mortality Associated with Influenza among Tuberculosis Deaths in South Africa, 1999-2009. PloS one 2015; 10(6):e0129173.
  16. Walaza S, Tempia S, Dawood H, Variava E, Moyes J, Cohen AL, et al. Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010-2011. BMC Infect Dis 2015; 15(1):26.
  17. Tempia S, Walaza S, Moyes J, McMorrow ML, Cohen AL, Edoka I, et al. Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015. Vaccine 2020; 38(27):4288-4297.
  18. National Insititute for Communicable Diseases. Increase in influenza cases in Western Cape Province. In: National Institute for Communicable Diseases; 2020.
  19. National Insititute for Communicable Diseases. Weekly respiratory pathogens surveillance report. In: National Institute for Communicable Diseases; 2021.
  20. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet InfectDis 2009; 9(8):493-504.
  21. Public Health England. PHE guidance on use of antiviral agents for the treatment and prophylaxis of influenza (2014-15). In; 2015. pp. 1-23.
  22. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Morbidity and mortality weekly report 2020; 69(44):1641-1647.
  23. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020; 370:m3320.
  24. Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoSMed 2011; 8(7):e1001053.
  25. Louie JK, Salibay CJ, Kang M, Glenn-Finer RE, Murray EL, Jamieson DJ. Pregnancy and severe influenza infection in the 2013-2014 influenza season. Obstetrics and gynecology 2015; 125(1):184-192.
  26. Cohen C, Simonsen L, Sample J, Kang JW, Miller M, Madhi SA, et al. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clin Infect Dis 2012; 55(7):996-1003.
  27. Puvanalingam A, Rajendiran C, Sivasubramanian K, Ragunanthanan S, Suresh S, Gopalakrishnan S. Case series study of the clinical profile of H1N1 swine flu influenza. JAssocPhysicians India 2011; 59:14-16, 18.
  28. Angelo SJ, Marshall PS, Chrissoheris MP, Chaves AM. Clinical characteristics associated with poor outcome in patients acutely infected with Influenza A. Connecticut medicine 2004; 68(4):199-205.
  29. Allard R, Leclerc P, Tremblay C, Tannenbaum TN. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes care 2010; 33(7):1491-1493.
  30. Fezeu L, Julia C, Henegar A, Bitu J, Hu FB, Grobbee DE, et al. Obesity is associated with higher risk of intensive care unit admission and death in influenza A (H1N1) patients: a systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity 2011; 12(8):653-659.
  31. Daley P, Castriciano S, Chernesky M, Smieja M. Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients. Journal of clinical microbiology 2006; 44(6):2265-2267.
  32. Heikkinen T, Marttila J, Salmi AA, Ruuskanen O. Nasal Swab versus Nasopharyngeal Aspirate for Isolation of Respiratory Viruses. Journal of clinical microbiology 2002; 40(11):4337-4339.
  33. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, et al. Epidemiology of Viral- associated Acute Lower Respiratory Tract Infection Among Children <5 Years of Age in a High HIV Prevalence Setting, South Africa, 2009-2012. The Pediatric infectious disease journal 2015; 34(1):66-72.
  34. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, et al. Epidemiology of Severe Acute Respiratory Illness (SARI) among Adults and Children Aged >/=5 Years in a High HIV- Prevalence Setting, 2009-2012. PloS one 2015; 10(2):e0117716.
  35. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355(9218):1845-1850.
  36. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. The Journal of infectious diseases 1999; 180(2):254-261.
  37. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. The Pediatric infectious disease journal 2001; 20(2):127-133.
  38. Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018; 66(10):1492-1500.
  39. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al MA, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet RespirMed 2014; 2(5):395-404.
  40. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. The Lancet; 385(9979):1729-1737.
  41. Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. In: Centers for Disease Control and Prevention; 2015.
  42. CDC. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2013–2014. In; 2013. pp. 1-43.
  43. Osterholm M, Kelley N, Sommer A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious diseases 2012; 12:36 - 44.
  44. McAnerney JM, Treurnicht F, Walaza S, Cohen AL, Tempia S, Mtshali S, et al. Evaluation of influenza vaccine effectiveness and description of circulating strains in outpatient settings in South Africa, 2014. Influenza and other respiratory viruses 2015; 9(4):209-215.
  45. Ntshoe GM, McAnerney JM, Tempia S, Blumberg L, Moyes J, Buys A, et al. Influenza epidemiology and vaccine effectiveness among patients with influenza-like illness, viral watch sentinel sites, South Africa, 2005-2009. PloS one 2014; 9(4):e94681.
  46. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, et al. Influenza vaccination of pregnant women and protection of their infants. The New England journal of medicine 2014; 371(10):918-931.
  47. Madhi SA, Nunes MC, Cutland CL. Influenza vaccination of pregnant women and protection of their infants. The New England journal of medicine 2014; 371(24):2340.
  48. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of Maternal Influenza Immunization in Mothers and Infants. New England Journal of Medicine 2008; 359(15):1555-1564.
  49. Eick AA, Uyeki TM, Klimov A, Hall H, Reid R, Santosham M, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 2011; 165(2):104- 111.
  50. Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52(1):128- 137.
  51. Madhi SA, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E, et al. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. Aids 2013; 27(3):369-379.
  52. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019 southern hemisphere influenza season. In; 2018. pp. 1-9.53.
  53. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2021southern hemisphere influenza season. In; 2020.
  54. Health NDo. COVID-19 Vaccination Messaging Guideline developed by the Communication Work Stream of the Technical Committee of the Inter-Ministerial Committee on Vaccinations - 8 March 2021. In; 2020.
  55. World Health Organization. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. In; 2010. pp. 32.

Influenza: NICD recommendations for the diagnosis, management, prevention and public health response, National institute of communicable diseases, 2021 

 

 

 

 

 

Drugs mentioned

NeoHealth® ID 24734 · updated 7/1/2022